Sarbjit Saini, MD
Allergy · Baltimore, MDNPI 1942235148
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $120,728 of the $174,047 with a category attached, or 69.4%. 13 manufacturers reported payments, led by Sanofi at 40.5% of the total. 2025 is the largest year on record at $56,118, more than ten times the $1,978 reported in 2019.
Across 95 payments — averaging $1832.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$70K
- Novartis$44K
- Celltrion, Inc.$24K
- Genentech USA, Inc.$16K
- Novartis Pharma AG$9K
- Regeneron$7K
- plus $4K from 7 others
Across 185 payments — averaging $10,796 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1M
- Regeneron$563K
- Sanofi US Services Inc.$241K
- Amgen$77K
- Eli Lilly$41K
- Gilead$31K
- plus $25K from 3 others
What the payments were for
- Consulting fees$120,72869%
- Speaking & faculty fees$21,70012%
- Travel & lodging$29,65717%
- Food & beverage$1,8631%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 37 | $70,470 |
| Novartis | 22 | $43,595 |
| Celltrion, Inc. | 6 | $23,991 |
| Genentech USA, Inc. | 12 | $16,407 |
| Novartis Pharma AG | 5 | $8,536 |
| Regeneron | 4 | $6,945 |
| GSK | 2 | $1,399 |
| Incyte Corporation | 1 | $953 |
| Alk-abello, Inc | 1 | $900 |
| Argenx US, Inc. | 1 | $600 |
| Genentech, Inc. | 2 | $156 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Optinose US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$174,047 in reported general payments places this provider in the 85th percentile of 29 allergy providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 16 | $154 |
Paid to pharmacies, not to this prescriber.
Other allergy in Baltimore
- David GoldenBaltimore$197K
- Jody TverskyBaltimore$175K
- Newton AdkinsonBaltimore$61K
- Peter CreticosBaltimore$22K
- Gitika DhillonBaltimore$8K
- Alkis TogiasBaltimore$67
- Huamin LiWheaton$576K
- Jonathan MatzWhite Marsh$147K
- Brett CoonsJb Andrews$49K
- David SchwartzBethesda$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.